New treatment launched for the symptomatic treatment of nocturia due to nocturnal polyuria

A new treatment called Noqdirna (oral lyophilisate desmopressin) for the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults has been launched following approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA).  Nocturia, the need to wake at night to pass urine, is a complex medical condition, impacting around 8.63 million people in the UK – night-time overproduction of urine, or nocturnal polyuria, is thought to contribute in up to 76–88% of these cases.  Nocturia can result in an increase in falls and fractures, due to the need for night-time bathroom trips or due to sleepiness during the day. In